AM 580

Drug Profile

AM 580

Alternative Names: AGN-190293; AM-580

Latest Information Update: 17 Nov 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator W.R. Grace
  • Developer Mitsubishi Pharma Corporation; Sumitomo Pharmaceuticals
  • Class Antineoplastics; Benzoic acids; Retinoids; Small molecules
  • Mechanism of Action Immunostimulants; Protein synthesis inhibitors; Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 06 Apr 2000 Yoshitomi is now called Welfide Corporation
  • 27 Sep 1999 A preclinical study has been added to the drug interactions section
  • 17 Apr 1997 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top